EXOZ vs MCRB vs ILMN vs TMO

For growth investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger pick with 3. 9% revenue growth year-over-year, versus -0. 8% for Illumina, Inc. (ILMN). Seres Therapeutics, Inc. (MCRB) offers the better valuation at 12. 1x trailing P/E, making it the more compelling value choice. Analysts rate Seres Therapeutics, Inc. (MCRB) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Seres Therapeutics, Inc.

(MCRB) is the cheapest at 12. 1x versus Thermo Fisher Scientific Inc. at 26. 8x. On forward P/E, Thermo Fisher Scientific Inc. is actually cheaper at 19. 1x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Illumina, Inc. wins at 6. 33x versus Thermo Fisher Scientific Inc. 's 9. 05x.

Over the past 5 years, eXoZymes, Inc.

(EXOZ) delivered a total return of +15. 6%, compared to -98. 1% for Seres Therapeutics, Inc. (MCRB). Over 10 years, the gap is even starker: TMO returned +229. 1% versus MCRB's -98. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), eXoZymes, Inc.

(EXOZ) is the lower-risk stock at 1. 04β versus Seres Therapeutics, Inc. 's 1. 69β — meaning MCRB is approximately 63% more volatile than EXOZ relative to the S&P 500. On balance sheet safety, eXoZymes, Inc. (EXOZ) carries a lower debt/equity ratio of 13% versus 188% for Seres Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Thermo Fisher Scientific Inc.

(TMO) is pulling ahead at 3. 9% versus -0. 8% for Illumina, Inc. (ILMN). On earnings-per-share growth, the picture is similar: Illumina, Inc. grew EPS 170. 9% year-over-year, compared to -188. 0% for eXoZymes, Inc.. Over a 3-year CAGR, TMO leads at -0. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Seres Therapeutics, Inc.

(MCRB) is the more profitable company, earning 721. 9% net margin versus 0. 0% for eXoZymes, Inc. — meaning it keeps 721. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ILMN leads at 19. 9% versus -119. 1% for MCRB. At the gross margin level — before operating expenses — ILMN leads at 66. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Illumina, Inc. (ILMN) is the more undervalued stock at a PEG of 6. 33x versus Thermo Fisher Scientific Inc. 's 9. 05x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Thermo Fisher Scientific Inc. (TMO) trades at 19. 1x forward P/E versus 26. 8x for Illumina, Inc. — 7. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for TMO: 38. 0% to $654. 67.

In this comparison, TMO (0.

4% yield) pays a dividend. EXOZ, MCRB, ILMN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Thermo Fisher Scientific Inc.

(TMO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 10), +229. 1% 10Y return). Seres Therapeutics, Inc. (MCRB) carries a higher beta of 1. 69 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TMO: +229. 1%, MCRB: -98. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: EXOZ is a small-cap quality compounder stock; MCRB is a small-cap deep-value stock; ILMN is a mid-cap quality compounder stock; TMO is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.